| GeneOntologyMolecularFunction | cysteine-type deubiquitinase activity | USP17L21 USP17L23 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.15e-22 | 114 | 49 | 15 | GO:0004843 |
| GeneOntologyMolecularFunction | deubiquitinase activity | USP17L21 USP17L23 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 4.34e-22 | 124 | 49 | 15 | GO:0101005 |
| GeneOntologyMolecularFunction | ubiquitin-like protein peptidase activity | USP17L21 USP17L23 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 2.07e-21 | 137 | 49 | 15 | GO:0019783 |
| GeneOntologyMolecularFunction | cysteine-type peptidase activity | USP17L21 USP17L23 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 3.78e-19 | 192 | 49 | 15 | GO:0008234 |
| GeneOntologyMolecularFunction | peptidase activity | USP17L21 USP17L23 USP17L12 USP17L17 ADAMTS6 USP17L20 USP17L11 USP17L24 USP24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.79e-12 | 654 | 49 | 16 | GO:0008233 |
| GeneOntologyMolecularFunction | structural constituent of postsynaptic actin cytoskeleton | POTEE POTEF POTEI | 2.26e-06 | 11 | 49 | 3 | GO:0098973 |
| GeneOntologyMolecularFunction | structural constituent of postsynapse | POTEE POTEF POTEI | 6.55e-05 | 32 | 49 | 3 | GO:0099186 |
| GeneOntologyMolecularFunction | structural constituent of synapse | POTEE POTEF POTEI | 1.49e-04 | 42 | 49 | 3 | GO:0098918 |
| GeneOntologyMolecularFunction | DNA-binding transcription factor activity, RNA polymerase II-specific | ZNF12 ZNF142 ZNF484 ZNF334 ZNF530 ZNF611 ZNF343 ZNF808 ZNF292 ZNF646 | 1.96e-03 | 1412 | 49 | 10 | GO:0000981 |
| GeneOntologyMolecularFunction | hyaluronic acid binding | USP17L24 USP17L6P | 2.30e-03 | 29 | 49 | 2 | GO:0005540 |
| GeneOntologyMolecularFunction | structural constituent of cytoskeleton | POTEE POTEF POTEI | 3.99e-03 | 130 | 49 | 3 | GO:0005200 |
| GeneOntologyBiologicalProcess | protein deubiquitination | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.73e-20 | 125 | 48 | 14 | GO:0016579 |
| GeneOntologyBiologicalProcess | protein modification by small protein removal | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.35e-19 | 144 | 48 | 14 | GO:0070646 |
| GeneOntologyBiologicalProcess | post-translational protein modification | USP17L21 PADI4 USP17L12 USP17L17 USP17L20 TRIM35 USP17L11 USP17L24 USP24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 TRIM48 USP17L13 USP17L18 | 1.23e-10 | 1074 | 48 | 17 | GO:0043687 |
| GeneOntologyBiologicalProcess | protein modification by small protein conjugation or removal | USP17L21 USP17L12 USP17L17 USP17L20 TRIM35 USP17L11 USP17L24 USP24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 TRIM48 USP17L13 USP17L18 | 4.92e-10 | 1009 | 48 | 16 | GO:0070647 |
| GeneOntologyBiologicalProcess | postsynaptic actin cytoskeleton organization | POTEE POTEF POTEI | 5.08e-05 | 31 | 48 | 3 | GO:0098974 |
| GeneOntologyBiologicalProcess | postsynaptic cytoskeleton organization | POTEE POTEF POTEI | 7.35e-05 | 35 | 48 | 3 | GO:0099188 |
| GeneOntologyBiologicalProcess | chorionic trophoblast cell differentiation | FZD5 MAP3K4 | 1.11e-04 | 7 | 48 | 2 | GO:0060718 |
| GeneOntologyBiologicalProcess | protein deubiquitination involved in ubiquitin-dependent protein catabolic process | USP17L24 USP17L6P | 1.47e-04 | 8 | 48 | 2 | GO:0071947 |
| GeneOntologyBiologicalProcess | chorion development | FZD5 MAP3K4 | 2.88e-04 | 11 | 48 | 2 | GO:0060717 |
| GeneOntologyBiologicalProcess | extraembryonic membrane development | FZD5 MAP3K4 | 4.74e-04 | 14 | 48 | 2 | GO:1903867 |
| GeneOntologyCellularComponent | endoplasmic reticulum membrane | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 2.59e-05 | 1293 | 48 | 12 | GO:0005789 |
| GeneOntologyCellularComponent | endoplasmic reticulum subcompartment | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 2.71e-05 | 1299 | 48 | 12 | GO:0098827 |
| GeneOntologyCellularComponent | nuclear outer membrane-endoplasmic reticulum membrane network | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 3.35e-05 | 1327 | 48 | 12 | GO:0042175 |
| GeneOntologyCellularComponent | H4/H2A histone acetyltransferase complex | POTEE POTEF POTEI | 5.38e-05 | 32 | 48 | 3 | GO:0043189 |
| GeneOntologyCellularComponent | NuA4 histone acetyltransferase complex | POTEE POTEF POTEI | 5.38e-05 | 32 | 48 | 3 | GO:0035267 |
| GeneOntologyCellularComponent | H4 histone acetyltransferase complex | POTEE POTEF POTEI | 1.51e-04 | 45 | 48 | 3 | GO:1902562 |
| GeneOntologyCellularComponent | histone acetyltransferase complex | POTEE POTEF POTEI | 1.32e-03 | 94 | 48 | 3 | GO:0000123 |
| GeneOntologyCellularComponent | protein acetyltransferase complex | POTEE POTEF POTEI | 1.76e-03 | 104 | 48 | 3 | GO:0031248 |
| GeneOntologyCellularComponent | acetyltransferase complex | POTEE POTEF POTEI | 2.01e-03 | 109 | 48 | 3 | GO:1902493 |
| GeneOntologyCellularComponent | actin filament | POTEE POTEF POTEI | 4.59e-03 | 146 | 48 | 3 | GO:0005884 |
| Domain | HABP4_PAI-RBP1 | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L5 USP17L19 USP17L22 USP17L13 USP17L18 | 2.40e-26 | 16 | 46 | 11 | PF04774 |
| Domain | HABP4_PAIRBP1-bd | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L5 USP17L19 USP17L22 USP17L13 USP17L18 | 2.40e-26 | 16 | 46 | 11 | IPR006861 |
| Domain | USP_CS | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP24 USP17L5 USP17L19 USP17L22 USP17L13 USP17L18 | 4.67e-20 | 66 | 46 | 12 | IPR018200 |
| Domain | USP_1 | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP24 USP17L5 USP17L19 USP17L22 USP17L13 USP17L18 | 1.00e-19 | 70 | 46 | 12 | PS00972 |
| Domain | UCH | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP24 USP17L5 USP17L19 USP17L22 USP17L13 USP17L18 | 1.20e-19 | 71 | 46 | 12 | PF00443 |
| Domain | USP_2 | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP24 USP17L5 USP17L19 USP17L22 USP17L13 USP17L18 | 1.20e-19 | 71 | 46 | 12 | PS00973 |
| Domain | USP_3 | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP24 USP17L5 USP17L19 USP17L22 USP17L13 USP17L18 | 1.44e-19 | 72 | 46 | 12 | PS50235 |
| Domain | USP_dom | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP24 USP17L5 USP17L19 USP17L22 USP17L13 USP17L18 | 1.44e-19 | 72 | 46 | 12 | IPR028889 |
| Domain | Peptidase_C19_UCH | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP24 USP17L5 USP17L19 USP17L22 USP17L13 USP17L18 | 1.44e-19 | 72 | 46 | 12 | IPR001394 |
| Domain | - | ZNF12 ZNF142 ZNF484 ZNF334 ZNF530 ZNF611 ZNF343 ZNF808 ZNF292 ZNF646 | 4.70e-06 | 679 | 46 | 10 | 3.30.160.60 |
| Domain | zf-C2H2 | ZNF12 ZNF142 ZNF484 ZNF334 ZNF530 ZNF611 ZNF343 ZNF808 ZNF292 ZNF646 | 5.63e-06 | 693 | 46 | 10 | PF00096 |
| Domain | Znf_C2H2/integrase_DNA-bd | ZNF12 ZNF142 ZNF484 ZNF334 ZNF530 ZNF611 ZNF343 ZNF808 ZNF292 ZNF646 | 5.71e-06 | 694 | 46 | 10 | IPR013087 |
| Domain | Actin_CS | POTEE POTEF POTEI | 7.66e-06 | 16 | 46 | 3 | IPR004001 |
| Domain | ACTINS_2 | POTEE POTEF POTEI | 9.28e-06 | 17 | 46 | 3 | PS00432 |
| Domain | Actin/actin-like_CS | POTEE POTEF POTEI | 1.11e-05 | 18 | 46 | 3 | IPR020902 |
| Domain | ACTINS_ACT_LIKE | POTEE POTEF POTEI | 1.32e-05 | 19 | 46 | 3 | PS01132 |
| Domain | ZINC_FINGER_C2H2_2 | ZNF12 ZNF142 ZNF484 ZNF334 ZNF530 ZNF611 ZNF343 ZNF808 ZNF292 ZNF646 | 1.50e-05 | 775 | 46 | 10 | PS50157 |
| Domain | ZINC_FINGER_C2H2_1 | ZNF12 ZNF142 ZNF484 ZNF334 ZNF530 ZNF611 ZNF343 ZNF808 ZNF292 ZNF646 | 1.53e-05 | 777 | 46 | 10 | PS00028 |
| Domain | Znf_C2H2-like | ZNF12 ZNF142 ZNF484 ZNF334 ZNF530 ZNF611 ZNF343 ZNF808 ZNF292 ZNF646 | 1.89e-05 | 796 | 46 | 10 | IPR015880 |
| Domain | Znf_C2H2 | ZNF12 ZNF142 ZNF484 ZNF334 ZNF530 ZNF611 ZNF343 ZNF808 ZNF292 ZNF646 | 2.08e-05 | 805 | 46 | 10 | IPR007087 |
| Domain | ZnF_C2H2 | ZNF12 ZNF142 ZNF484 ZNF334 ZNF530 ZNF611 ZNF343 ZNF808 ZNF292 ZNF646 | 2.15e-05 | 808 | 46 | 10 | SM00355 |
| Domain | KRAB | ZNF12 ZNF484 ZNF334 ZNF530 ZNF611 ZNF343 ZNF808 | 2.52e-05 | 358 | 46 | 7 | PS50805 |
| Domain | KRAB | ZNF12 ZNF484 ZNF334 ZNF530 ZNF611 ZNF343 ZNF808 | 2.52e-05 | 358 | 46 | 7 | PF01352 |
| Domain | KRAB | ZNF12 ZNF484 ZNF334 ZNF530 ZNF611 ZNF343 ZNF808 | 3.06e-05 | 369 | 46 | 7 | SM00349 |
| Domain | KRAB | ZNF12 ZNF484 ZNF334 ZNF530 ZNF611 ZNF343 ZNF808 | 3.11e-05 | 370 | 46 | 7 | IPR001909 |
| Domain | Actin | POTEE POTEF POTEI | 5.99e-05 | 31 | 46 | 3 | IPR004000 |
| Domain | Actin | POTEE POTEF POTEI | 5.99e-05 | 31 | 46 | 3 | PF00022 |
| Domain | ACTIN | POTEE POTEF POTEI | 5.99e-05 | 31 | 46 | 3 | SM00268 |
| Domain | zf-C2H2_6 | ZNF12 ZNF334 ZNF530 ZNF611 ZNF808 ZNF646 | 1.14e-04 | 314 | 46 | 6 | PF13912 |
| Domain | ASX_HYDROXYL | SCUBE1 CELSR3 DLL1 | 1.91e-03 | 100 | 46 | 3 | PS00010 |
| Domain | EGF-type_Asp/Asn_hydroxyl_site | SCUBE1 CELSR3 DLL1 | 2.26e-03 | 106 | 46 | 3 | IPR000152 |
| Domain | EGF_3 | SCUBE1 CELSR3 DLL1 SSPOP | 2.63e-03 | 235 | 46 | 4 | PS50026 |
| Domain | EGF_CA | SCUBE1 CELSR3 DLL1 | 3.36e-03 | 122 | 46 | 3 | SM00179 |
| Domain | EGF-like_Ca-bd_dom | SCUBE1 CELSR3 DLL1 | 3.52e-03 | 124 | 46 | 3 | IPR001881 |
| Domain | EGF_1 | SCUBE1 CELSR3 DLL1 SSPOP | 3.53e-03 | 255 | 46 | 4 | PS00022 |
| Domain | EGF_2 | SCUBE1 CELSR3 DLL1 SSPOP | 4.05e-03 | 265 | 46 | 4 | PS01186 |
| Pathway | REACTOME_RAS_PROCESSING | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 8.29e-22 | 45 | 39 | 12 | MM15671 |
| Pathway | REACTOME_UB_SPECIFIC_PROCESSING_PROTEASES | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 2.05e-15 | 191 | 39 | 13 | MM15289 |
| Pathway | REACTOME_UB_SPECIFIC_PROCESSING_PROTEASES | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP24 USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.38e-14 | 221 | 39 | 13 | M27578 |
| Pathway | REACTOME_DEUBIQUITINATION | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.24e-13 | 262 | 39 | 13 | MM15286 |
| Pathway | REACTOME_DEUBIQUITINATION | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP24 USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 6.72e-13 | 299 | 39 | 13 | M27574 |
| Pathway | REACTOME_MAPK_FAMILY_SIGNALING_CASCADES | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 3.20e-11 | 318 | 39 | 12 | MM15278 |
| Pathway | REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION | USP17L21 USP17L12 USP17L17 ADAMTS6 USP17L20 USP17L11 USP17L24 USP24 OBSL1 USP17L5 USP17L19 USP17L22 SSPOP USP17L15 USP17L13 USP17L18 | 6.89e-07 | 1475 | 39 | 16 | M19806 |
| Pathway | REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION | USP17L21 USP17L12 USP17L17 ADAMTS6 USP17L20 USP17L11 USP24 USP17L6P USP17L5 USP17L19 USP17L22 SSPOP USP17L15 USP17L13 USP17L18 | 1.90e-06 | 1389 | 39 | 15 | MM15307 |
| Pathway | PID_BETA_CATENIN_DEG_PATHWAY | FZD5 SSPOP | 1.11e-03 | 18 | 39 | 2 | M31 |
| Pubmed | DUB-2A, a new member of the DUB subfamily of hematopoietic deubiquitinating enzymes. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 4.12e-30 | 21 | 49 | 12 | 11468161 |
| Pubmed | The murine DUB-1 gene is specifically induced by the betac subunit of interleukin-3 receptor. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 4.12e-30 | 21 | 49 | 12 | 8756639 |
| Pubmed | DUB-1, a deubiquitinating enzyme with growth-suppressing activity. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 4.12e-30 | 21 | 49 | 12 | 8622927 |
| Pubmed | DUB-1A, a novel deubiquitinating enzyme subfamily member, is polyubiquitinated and cytokine-inducible in B-lymphocytes. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 4.12e-30 | 21 | 49 | 12 | 14583620 |
| Pubmed | Lymphocyte-specific murine deubiquitinating enzymes induced by cytokines. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 4.12e-30 | 21 | 49 | 12 | 12447969 |
| Pubmed | DUB-1, a fate determinant of dynein heavy chain in B-lymphocytes, is regulated by the ubiquitin-proteasome pathway. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 4.12e-30 | 21 | 49 | 12 | 18980247 |
| Pubmed | Cdc25A and Dub3 in a high-stakes balancing act. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 8.46e-30 | 33 | 49 | 13 | 20228807 |
| Pubmed | JAK2 is required for induction of the murine DUB-1 gene. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 9.05e-30 | 22 | 49 | 12 | 9154835 |
| Pubmed | Polyclonal and monoclonal antibodies specific for USP17, a proapoptotic deubiquitinating enzyme. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.37e-29 | 34 | 49 | 13 | 20715989 |
| Pubmed | Human megasatellite DNA RS447: copy-number polymorphisms and interspecies conservation. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.37e-29 | 34 | 49 | 13 | 9806828 |
| Pubmed | The ubiquitin-specific protease 17 is involved in virus-triggered type I IFN signaling. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.37e-29 | 34 | 49 | 13 | 20368735 |
| Pubmed | The DUB/USP17 deubiquitinating enzymes, a multigene family within a tandemly repeated sequence. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.37e-29 | 34 | 49 | 13 | 15780755 |
| Pubmed | The DUB/USP17 deubiquitinating enzymes: a gene family within a tandemly repeated sequence, is also embedded within the copy number variable beta-defensin cluster. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.37e-29 | 34 | 49 | 13 | 20403174 |
| Pubmed | USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.37e-29 | 34 | 49 | 13 | 19188362 |
| Pubmed | Hyaluronan- and RNA-binding deubiquitinating enzymes of USP17 family members associated with cell viability. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.37e-29 | 34 | 49 | 13 | 17109758 |
| Pubmed | Unstable transmission of the RS447 human megasatellite tandem repetitive sequence that contains the USP17 deubiquitinating enzyme gene. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.37e-29 | 34 | 49 | 13 | 11941478 |
| Pubmed | The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.37e-29 | 34 | 49 | 13 | 20388806 |
| Pubmed | DUB-3, a cytokine-inducible deubiquitinating enzyme that blocks proliferation. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.37e-29 | 34 | 49 | 13 | 14699124 |
| Pubmed | The RS447 human megasatellite tandem repetitive sequence encodes a novel deubiquitinating enzyme with a functional promoter. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.37e-29 | 34 | 49 | 13 | 10936051 |
| Pubmed | The deubiquitinating enzyme USP17 is essential for GTPase subcellular localization and cell motility. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.37e-29 | 34 | 49 | 13 | 21448158 |
| Pubmed | Lys-63-specific deubiquitination of SDS3 by USP17 regulates HDAC activity. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 2.17e-29 | 35 | 49 | 13 | 21239494 |
| Pubmed | Cytokine-regulated protein degradation by the ubiquitination system. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 2.17e-29 | 35 | 49 | 13 | 16611142 |
| Pubmed | The deubiquitinating enzyme USP17 blocks N-Ras membrane trafficking and activation but leaves K-Ras unaffected. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 3.40e-29 | 36 | 49 | 13 | 20147298 |
| Pubmed | DUB-2 is a member of a novel family of cytokine-inducible deubiquitinating enzymes. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 3.78e-29 | 24 | 49 | 12 | 8995226 |
| Pubmed | Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 5.24e-29 | 37 | 49 | 13 | 20228808 |
| Pubmed | Interleukin 1 receptor signaling regulates DUBA expression and facilitates Toll-like receptor 9-driven antiinflammatory cytokine production. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 7.26e-29 | 25 | 49 | 12 | 21115691 |
| Pubmed | Decabromodiphenyl ethane affects embryonic development by interfering with nuclear F-actin in zygotes and leads to cognitive and social disorders in offspring mice. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.35e-28 | 26 | 49 | 12 | 35816173 |
| Pubmed | Minor Splicing Factors Zrsr1 and Zrsr2 Are Essential for Early Embryo Development and 2-Cell-Like Conversion. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 7.22e-28 | 29 | 49 | 12 | 32527007 |
| Pubmed | DUX is a non-essential synchronizer of zygotic genome activation. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.65e-24 | 50 | 49 | 12 | 31806660 |
| Pubmed | USP7 represses lineage differentiation genes in mouse embryonic stem cells by both catalytic and noncatalytic activities. | USP17L21 PADI4 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 6.71e-12 | 674 | 49 | 13 | 37196079 |
| Pubmed | A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L19 USP17L18 | 3.50e-10 | 119 | 49 | 7 | 28625976 |
| Pubmed | Identification of a novel actin isoform in hepatocellular carcinoma. | POTEE POTEF POTEI | 1.18e-06 | 15 | 49 | 3 | 16824795 |
| Pubmed | A primate-specific POTE-actin fusion protein plays a role in apoptosis. | POTEE POTEF | 1.94e-06 | 2 | 49 | 2 | 19669888 |
| Pubmed | CXCR3 determines strain susceptibility to murine cerebral malaria by mediating T lymphocyte migration toward IFN-gamma-induced chemokines. | IFNGR1 CXCR3 | 5.83e-06 | 3 | 49 | 2 | 18383042 |
| Pubmed | Interferon-gamma-dependent mechanisms of mycobacteria-induced pulmonary immunopathology: the role of angiostasis and CXCR3-targeted chemokines for granuloma necrosis. | IFNGR1 CXCR3 | 5.83e-06 | 3 | 49 | 2 | 17534845 |
| Pubmed | Evolution and expression of chimeric POTE-actin genes in the human genome. | POTEE POTEF | 5.83e-06 | 3 | 49 | 2 | 17101985 |
| Pubmed | Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. | IFNGR1 CXCR3 | 1.16e-05 | 4 | 49 | 2 | 26831100 |
| Pubmed | Endotoxin augmented antigen-induced Th1 cell trafficking amplifies airway neutrophilic inflammation. | IFNGR1 CXCR3 | 1.16e-05 | 4 | 49 | 2 | 19494319 |
| Pubmed | IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms. | IFNGR1 CXCR3 | 1.16e-05 | 4 | 49 | 2 | 20061409 |
| Pubmed | Embryonic demise caused by targeted disruption of a cysteine protease Dub-2. | USP17L15 USP17L13 | 1.16e-05 | 4 | 49 | 2 | 22984479 |
| Pubmed | Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. | IFNGR1 PADI4 | 1.16e-05 | 4 | 49 | 2 | 24425713 |
| Pubmed | Interferon-γ mediates chemokine-dependent recruitment of natural killer cells during viral infection. | IFNGR1 CXCR3 | 1.94e-05 | 5 | 49 | 2 | 23248310 |
| Pubmed | CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. | IFNGR1 CXCR3 | 1.94e-05 | 5 | 49 | 2 | 19898495 |
| Pubmed | CXCL10 chemokine regulates heterogeneity of the CD8+ T cell response and viral set point during chronic infection. | IFNGR1 CXCR3 | 1.94e-05 | 5 | 49 | 2 | 34847356 |
| Pubmed | Influenza Vaccination Induces NK-Cell-Mediated Type-II IFN Response that Regulates Humoral Immunity in an IL-6-Dependent Manner. | IFNGR1 CXCR3 | 2.91e-05 | 6 | 49 | 2 | 30811982 |
| Pubmed | The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. | IFNGR1 CXCR3 | 2.91e-05 | 6 | 49 | 2 | 19412181 |
| Pubmed | Interferon-γ production by Tfh cells is required for CXCR3+ pre-memory B cell differentiation and subsequent lung-resident memory B cell responses. | IFNGR1 CXCR3 | 4.07e-05 | 7 | 49 | 2 | 37699392 |
| Pubmed | The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. | FZD5 DLL1 | 5.42e-05 | 8 | 49 | 2 | 12839624 |
| Pubmed | CXCR3 and its ligands in a murine model of obliterative bronchiolitis: regulation and function. | IFNGR1 CXCR3 | 5.42e-05 | 8 | 49 | 2 | 16709871 |
| Pubmed | Characterization of a mouse multigene family that encodes zinc finger structures. | ZNF12 ZNF292 | 5.42e-05 | 8 | 49 | 2 | 2452975 |
| Pubmed | Migratory Dendritic Cells, Group 1 Innate Lymphoid Cells, and Inflammatory Monocytes Collaborate to Recruit NK Cells to the Virus-Infected Lymph Node. | IFNGR1 CXCR3 | 5.42e-05 | 8 | 49 | 2 | 29972776 |
| Pubmed | Duplication and extensive remodeling shaped POTE family genes encoding proteins containing ankyrin repeat and coiled coil domains. | POTEE POTEI | 6.96e-05 | 9 | 49 | 2 | 16364570 |
| Pubmed | Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer. | IFNGR1 CXCR3 | 6.96e-05 | 9 | 49 | 2 | 36736322 |
| Pubmed | High Dub3 expression in mouse ESCs couples the G1/S checkpoint to pluripotency. | USP17L6P USP17L15 | 8.69e-05 | 10 | 49 | 2 | 24207026 |
| Pubmed | Cell cycle-dependent expression of Dub3, Nanog and the p160 family of nuclear receptor coactivators (NCoAs) in mouse embryonic stem cells. | USP17L6P USP17L15 | 1.27e-04 | 12 | 49 | 2 | 24695638 |
| Pubmed | ES cell neural differentiation reveals a substantial number of novel ESTs. | USP17L6P USP17L15 | 1.75e-04 | 14 | 49 | 2 | 11793228 |
| Pubmed | Lack of cadherins Celsr2 and Celsr3 impairs ependymal ciliogenesis, leading to fatal hydrocephalus. | CELSR3 SSPOP | 2.02e-04 | 15 | 49 | 2 | 20473291 |
| Pubmed | Human and mouse proteases: a comparative genomic approach. | USP24 USP17L6P USP17L15 | 2.08e-04 | 81 | 49 | 3 | 12838346 |
| Pubmed | Rotatin is a novel gene required for axial rotation and left-right specification in mouse embryos. | RTTN DLL1 | 2.30e-04 | 16 | 49 | 2 | 11900971 |
| Pubmed | CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. | USP17L6P USP17L15 | 3.27e-04 | 19 | 49 | 2 | 28067227 |
| Pubmed | Shotgun proteomics reveals specific modulated protein patterns in tears of patients with primary open angle glaucoma naïve to therapy. | POTEE POTEF POTEI | 3.42e-04 | 96 | 49 | 3 | 23580065 |
| Pubmed | Generation and annotation of the DNA sequences of human chromosomes 2 and 4. | USP17L23 FZD5 POTEF USP17L5 POTEI | 3.90e-04 | 442 | 49 | 5 | 15815621 |
| Pubmed | The zinc-finger protein basonuclin 2 is required for proper mitotic arrest, prevention of premature meiotic initiation and meiotic progression in mouse male germ cells. | NANOS2 INSL3 | 5.71e-04 | 25 | 49 | 2 | 25344072 |
| Pubmed | Impaired plasma membrane localization of ubiquitin ligase complex underlies 3-M syndrome development. | ZNF12 POTEE RTTN ZNF611 OBSL1 | 6.58e-04 | 496 | 49 | 5 | 31343991 |
| Pubmed | New interaction partners for Nek4.1 and Nek4.2 isoforms: from the DNA damage response to RNA splicing. | POTEE CELSR3 ADAMTS6 POTEF RCOR3 | 7.65e-04 | 513 | 49 | 5 | 25798074 |
| Pubmed | Female-to-male sex reversal in mice caused by transgenic overexpression of Dmrt1. | NANOS2 INSL3 | 9.39e-04 | 32 | 49 | 2 | 25725066 |
| Pubmed | Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach. | POTEE POTEF POTEI | 1.23e-03 | 149 | 49 | 3 | 22664934 |
| Interaction | FLT3 interactions | TTF2 USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L19 USP17L18 | 5.45e-07 | 318 | 46 | 8 | int:FLT3 |
| Cytoband | 4p16.1 | USP17L21 USP17L23 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 3.79e-28 | 79 | 49 | 14 | 4p16.1 |
| Cytoband | Ensembl 112 genes in cytogenetic band chr4p16 | USP17L21 USP17L23 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.47e-21 | 222 | 49 | 14 | chr4p16 |
| Cytoband | 2q21.1 | POTEE POTEF POTEI | 3.38e-05 | 58 | 49 | 3 | 2q21.1 |
| Cytoband | Ensembl 112 genes in cytogenetic band chr2q21 | POTEE POTEF POTEI | 5.75e-04 | 151 | 49 | 3 | chr2q21 |
| Cytoband | 19q13.41 | ZNF611 ZNF808 | 3.18e-03 | 78 | 49 | 2 | 19q13.41 |
| Cytoband | 2q35 | ZNF142 OBSL1 | 3.26e-03 | 79 | 49 | 2 | 2q35 |
| Cytoband | Ensembl 112 genes in cytogenetic band chr2q35 | ZNF142 OBSL1 | 8.45e-03 | 129 | 49 | 2 | chr2q35 |
| GeneFamily | Zinc fingers C2H2-type|ZF class homeoboxes and pseudogenes | ZNF12 ZNF142 ZNF484 ZNF334 ZNF530 ZNF611 ZNF343 ZNF808 ZNF292 ZNF646 | 1.34e-07 | 718 | 30 | 10 | 28 |
| GeneFamily | Ankyrin repeat domain containing|POTE ankyrin domain containing | POTEE POTEF POTEI | 1.17e-06 | 13 | 30 | 3 | 685 |
| GeneFamily | Ankyrin repeat domain containing | POTEE POTEF POTEI | 7.36e-03 | 242 | 30 | 3 | 403 |
| GeneFamily | Ring finger proteins|Tripartite motif containing|ARF GTPase family | TRIM35 TRIM48 | 1.08e-02 | 95 | 30 | 2 | 59 |
| Coexpression | MADAN_DPPA4_TARGETS | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 2.49e-20 | 86 | 46 | 12 | MM1312 |
| Coexpression | GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_DN | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 6.96e-19 | 112 | 46 | 12 | MM1095 |
| Coexpression | GERY_CEBP_TARGETS | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 5.73e-17 | 160 | 46 | 12 | MM1155 |
| Coexpression | GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP | USP17L21 USP17L12 USP17L17 USP17L20 FZD5 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 5.40e-11 | 647 | 46 | 13 | MM981 |
| Coexpression | BRUINS_UVC_RESPONSE_LATE | USP17L21 CELSR3 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 SGSM3 USP17L22 USP17L15 USP17L13 USP17L18 | 9.79e-09 | 1198 | 46 | 14 | MM1062 |
| Coexpression | GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP | USP17L21 USP17L12 USP17L17 USP17L20 FZD5 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.16e-07 | 1226 | 46 | 13 | MM979 |
| Coexpression | MARSON_BOUND_BY_FOXP3_STIMULATED | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 2.21e-07 | 1072 | 46 | 12 | MM1031 |
| CoexpressionAtlas | facebase_RNAseq_e8.5_NeuroEpith_nonFloor_2500_K1 | FZD5 DLL1 NUAK2 | 2.16e-05 | 35 | 33 | 3 | facebase_RNAseq_e8.5_NeuroEpith_nonFloor_2500_K1 |
| Disease | primary ovarian insufficiency (implicated_via_orthology) | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 4.86e-27 | 46 | 46 | 13 | DOID:5426 (implicated_via_orthology) |
| Disease | congenital heart disease (implicated_via_orthology) | USP17L21 USP17L12 USP17L17 USP17L20 USP17L11 USP17L24 USP17L6P USP17L5 USP17L19 USP17L22 USP17L15 USP17L13 USP17L18 | 1.80e-24 | 69 | 46 | 13 | DOID:1682 (implicated_via_orthology) |
| Disease | macrophage inflammatory protein 1a measurement | SCUBE1 RTTN | 1.14e-03 | 32 | 46 | 2 | EFO_0008218 |
| Disease | Seizures | ZNF142 DLL1 ZNF292 | 4.78e-03 | 218 | 46 | 3 | C0036572 |
| Disease | Intellectual Disability | ZNF142 RTTN DLL1 ZNF292 | 5.13e-03 | 447 | 46 | 4 | C3714756 |
| Disease | dilated cardiomyopathy (implicated_via_orthology) | CXCR3 DLL1 | 6.95e-03 | 80 | 46 | 2 | DOID:12930 (implicated_via_orthology) |
